The 4th Inflammasome Therapeutics Summit is the only industry-led forum uniting large pharma, biotechs, and academic KOLs, with the common goal of accelerating the practical translation and clinical development of inflammasome-targeted drugs, which are shaking up the immunology R&D landscape.

As the space eagerly awaits data readouts from proof-of-concept trials, and with more companies than ever before with active inflammasome therapeutic pipelines; this is your opportunity to be involved in interactive discussions on:

• Deciphering the intricate mechanisms underlying dysregulated inflammasome signaling within the wider context of the immune system
• Overcoming limitations of preclinical models, identifying clinically meaningful biomarkers of inflammasome inhibition, and defining good clinical endpoints
• Taming inflammation and achieving optimized safety profiles using the next frontier for inflammasome-targeted drugs including those targeting NLRP3 and novel targets
• Delving into specific disease groups to demonstrate where inflammasome therapeutics will be most impactful

Join 120+ fellow peers and industry heavyweights this Fall including NodThera, Novartis, Zyversa Therapeutics, and more, to build meaningful partnerships and propel the next frontier of inflammasome therapeutics from pipeline development into a clinical and commercial reality.

Access the official event guide here to learn more.